» Articles » PMID: 36013962

Role of the Gut-Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinson's Disease

Overview
Journal Microorganisms
Specialty Microbiology
Date 2022 Aug 26
PMID 36013962
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is the second-most prevalent neurodegenerative or neuropsychiatric disease, affecting 1% of seniors worldwide. The gut microbiota (GM) is one of the key access controls for most diseases and disorders. Disturbance in the GM creates an imbalance in the function and circulation of metabolites, resulting in unhealthy conditions. Any dysbiosis could affect the function of the gut, consequently disturbing the equilibrium in the intestine, and provoking pro-inflammatory conditions in the gut lumen, which send signals to the central nervous system (CNS) through the vagus enteric nervous system, possibly disturbing the blood-brain barrier. The neuroinflammatory conditions in the brain cause accumulation of α-syn, and progressively develop PD. An important aspect of understanding and treating the disease is access to broad knowledge about the influence of dietary supplements on GM. Probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit on the host. Probiotic supplementation improves the function of the CNS, and improves the motor and non-motor symptoms of PD. Probiotic supplementation could be an adjuvant therapeutic method to manage PD. This review summarizes the role of GM in health, the GM-brain axis, the pathogenesis of PD, the role of GM and diet in PD, and the influence of probiotic supplementation on PD. The study encourages further detailed clinical trials in PD patients with probiotics, which aids in determining the involvement of GM, intestinal mediators, and neurological mediators in the treatment or management of PD.

Citing Articles

Gut Microbiota-Based Interventions for Parkinson's Disease: Neuroprotective Mechanisms and Current Perspective.

Kumar D, Bishnoi M, Kondepudi K, Sharma S Probiotics Antimicrob Proteins. 2025; .

PMID: 39809955 DOI: 10.1007/s12602-024-10433-x.


Editorial: Reviews in neuropharmacology 2023: microbiota gut-brain axis, therapeutic insights for neurodegenerative diseases.

Sivamaruthi B, Suganthy N, Pellegrini C Front Pharmacol. 2024; 15:1499072.

PMID: 39421670 PMC: 11484058. DOI: 10.3389/fphar.2024.1499072.


The Interaction Between Nutraceuticals and Gut Microbiota: a Novel Therapeutic Approach to Prevent and Treatment Parkinson's Disease.

Yao L, Yang Y, Yang X, Rezaei M Mol Neurobiol. 2024; 61(11):9078-9109.

PMID: 38587699 DOI: 10.1007/s12035-024-04151-2.


Is Beneficial to a Mouse Model of Parkinson's Disease, via Alleviated Neuroinflammation and Promoted Neurogenesis, with Involvement of SCFAs.

Qiao C, Huang W, Zhou Y, Quan W, Niu G, Li T Brain Sci. 2024; 14(3).

PMID: 38539626 PMC: 10968773. DOI: 10.3390/brainsci14030238.


Probiotic ZW3 Alleviates DSS-Induced Colitis and Enhances Gut Homeostasis.

Jia D, Li Y, Wang Y, Guo Y, Liu J, Zhao S Int J Mol Sci. 2024; 25(1).

PMID: 38203732 PMC: 10778761. DOI: 10.3390/ijms25010561.


References
1.
Ibrahim A, Ali R, Abdul Manaf M, Ahmad N, Tajurruddin F, Qin W . Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial. PLoS One. 2020; 15(12):e0244680. PMC: 7774928. DOI: 10.1371/journal.pone.0244680. View

2.
Sivamaruthi B, Kesika P, Chaiyasut C . Impact of Fermented Foods on Human Cognitive Function-A Review of Outcome of Clinical Trials. Sci Pharm. 2018; 86(2). PMC: 6027668. DOI: 10.3390/scipharm86020022. View

3.
Azad M, Sarker M, Li T, Yin J . Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018; 2018:9478630. PMC: 5964481. DOI: 10.1155/2018/9478630. View

4.
Lin A, Zheng W, He Y, Tang W, Wei X, He R . Gut microbiota in patients with Parkinson's disease in southern China. Parkinsonism Relat Disord. 2018; 53:82-88. DOI: 10.1016/j.parkreldis.2018.05.007. View

5.
Hornykiewicz O . The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006; (70):9-15. DOI: 10.1007/978-3-211-45295-0_3. View